Related Experiment Video
Updated: May 16, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation
Mark J Alberts1, John W Eikelboom, Graeme J Hankey
1Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
Insights
New oral anticoagulants offer effective stroke risk reduction for atrial fibrillation (AF) patients. These agents are as safe and effective as warfarin, with added benefits like fewer drug interactions and reduced intracranial bleeding.
Area of Science:
- Cardiology
- Pharmacology
- Neurology
Background:
- Atrial fibrillation (AF) is a growing global health concern, leading to a significant burden of stroke.
- Current stroke risk stratification tools include CHADS(2) and CHA(2)DS(2)VASc scores.
- Effective anticoagulation can reduce AF-related stroke risk by two-thirds, yet Vitamin K antagonists like warfarin are often underused or poorly managed.
Purpose of the Study:
- To evaluate the efficacy and safety of new oral anticoagulants (NOACs) compared to warfarin for stroke prevention in atrial fibrillation.
- To highlight the advantages and disadvantages of NOACs in clinical practice.
Main Methods:
- Comparative analysis of NOACs (dabigatran etexilate, rivaroxaban, apixaban) against warfarin.
- Review of clinical trial data assessing efficacy, safety, drug interactions, and bleeding profiles.
Main Results:
- NOACs demonstrate comparable efficacy and safety to warfarin in preventing stroke in AF patients.
- NOACs offer predictable anticoagulant effects, minimal drug interactions, and lower rates of intracranial hemorrhage.
- Potential disadvantages include the need for validated antidotes and standardized monitoring tests, and possible increased gastrointestinal bleeding and cost.
Conclusions:
- NOACs represent a significant advancement in anticoagulation therapy for atrial fibrillation.
- These agents are expected to improve optimal anticoagulation rates in at-risk patients, thereby reducing the incidence of AF-related strokes.
Abstract:
The world faces an epidemic of atrial fibrillation and atrial fibrillation-related stroke. An individual's risk of atrial fibrillation-related stroke can be estimated with the CHADS(2) or CHA(2)DS(2)VASc scores, and reduced by two-thirds with effective anticoagulation. Vitamin K antagonists, such as warfarin, are underused and often poorly managed. The direct thrombin inhibitor dabigatran etexilate and factor Xa inhibitors rivaroxaban and apixaban are new oral anticoagulants that are at least as efficacious and safe as warfarin. Their advantages are predictable anticoagulant effects, low propensity for drug interactions, and lower rates of intracranial haemorrhage than with warfarin. A disadvantage is the continuing need to develop and validate rapidly effective antidotes for major bleeding and standardised tests that accurately measure plasma concentrations and anticoagulant effects, together with the disadvantage of possible higher rates of gastrointestinal haemorrhage and greater expense than with warfarin. The new oral anticoagulants should increase the number of patients with atrial fibrillation at risk of stroke who are optimally anticoagulated, and reduce the burden of atrial fibrillation-related stroke.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Venous Thrombosis IV: Nursing Management
01:26Atherosclerosis III: Management